Samba Signs CDMO Agreement with Enzolytics, Developer of COVID-19 Antibody Therapeutics
[Asia Economy Reporter Chunhee Lee] Samsung Biologics announced on the 8th that it has signed a contract for contract development and manufacturing organization (CDMO) services with the U.S. antibody therapeutic developer Enzolytics.
Under this contract, Samsung Biologics will provide end-to-end CDMO services from cell line development to clinical material production and Investigational New Drug (IND) application support for Enzolytics' COVID-19 monoclonal antibody therapeutic and human immunodeficiency virus (HIV) monoclonal antibody therapeutic for acquired immunodeficiency syndrome (AIDS). Discussions will also be held for contracts related to other antibody therapeutics currently being developed by Enzolytics.
Enzolytics is developing antibody therapeutics targeting immutable sites within viruses based on an artificial intelligence (AI) platform, enabling response to variant viruses. Samsung Biologics will support Enzolytics' cell line development through its contract development and manufacturing (CDO) research and development (R&D) center in San Francisco, USA. Clinical material production will be carried out at the headquarters in Songdo, Incheon.
John Rim, CEO of Samsung Biologics, said, "We are confident that Enzolytics will successfully achieve its goals through the world's most competitive end-to-end CDMO services," adding, "We will do our best to accelerate new drug development and ensure that therapeutics are promptly supplied to patients worldwide based on high-quality services and expertise."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Gaurav Chandra, Chief Operating Officer (COO) of Enzolytics, also said, "We decided on this collaboration considering Samsung Biologics' extensive experience and expertise in the development, production, and manufacturing of monoclonal antibody therapeutics," adding, "We will ensure that patients receive treatment in a timely manner by shortening the clinical and development timelines for monoclonal antibody therapeutics."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
